Unique ID issued by UMIN | UMIN000015538 |
---|---|
Receipt number | R000017746 |
Scientific Title | A multicentre, long-term administration study of KN01 in patients with mitochondrial encephalomyopathy(MELAS) |
Date of disclosure of the study information | 2014/10/27 |
Last modified on | 2019/02/25 11:10:53 |
A multicentre, long-term administration study of KN01 in patients with mitochondrial encephalomyopathy(MELAS)
MELAS-taurine long-term study
A multicentre, long-term administration study of KN01 in patients with mitochondrial encephalomyopathy(MELAS)
MELAS-taurine long-term study
Japan |
motochondrial encephalomyopathy (MELAS)
Neurology |
Others
YES
To investigate the safety of long-term taurine supplementation therapy for prevention of stroke-like episodes in patients with MELAS
Safety
Confirmatory
Phase III
safety: adverse events and adverse effects
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Medicine |
taurine supplementation
Not applicable |
Not applicable |
Male and Female
(1)MELAS patients who participated in the multiceentre trial of KN01 (KN01-MELAS-01:UMIN000011908).
(2)Adult patients who agree to participate in the clinical trial and sign the written informed consent document. Children patients who cannot autonomously provide informed consent are required to give informed assent by themselves. Instead, their parents sign the written informed consent document.
(1) Patients can not be conducted by head MRI scan because of pacemaker implantation, etc.
(2) Patients with severe coma or status epileptics
(3) Patients incapable of communication due to dementia, bedridden, etc.,
(4) Patients with merger sepsis
(5) Patients with severe impairment in cardiac, liver, or renal function
(6) Patients in need of systemic administration of steroids for a long period of time (2 weeks or more)
(7) Patients with pyruvate in 12 weeks before obtaining informed consent
(8) Patients who are pregnant or lactating, or may be pregnant
(9) Patients with history of hypersensitivity to the component of study drug
(10)Ppatients with history of drug allergy
(11) Patients who participated in clinical trials within 12 weeks before obtaining informed consent
(12) Other, patients whom physician or investigator has determined disqualified as participants
10
1st name | |
Middle name | |
Last name | Yoshihide Sunada |
Kawasaki Medical School
Neurology
577 Matsushima,Kurashiki-city,Okayama 701-0192 Japan
086-462-1111
ysunada@med.kawasaki-m.ac.jp
1st name | |
Middle name | |
Last name | Mai Moriyama |
CTD inc.
Medicinal Products Promotion Division
3-3-2, Tsukiji, Chuo-ku, Tokyo
03-6228-4105
https://www.c-ctd.co.jp/project_sn01/researcher/contents/documents.html
taurine@c-ctd.co.jp
Kawasaki Medical School Hospital
Kawasaki Medical School
Other
National Defense Medical College Hospital
Seirei Hamamatsu General Hospital
Fujita Health University School of Medicine
National Hospital Organization Kyoto Medical Center
Hyogo-Chuo National Hospital
Fukuoka University Chikushi Hospital
Nagasaki University Hospital
Hiroshima University Hospital
Nippon Medical School
National Center of Neurology and Psychiatry
Teikyo University of Science
NO
9月8日
2014 | Year | 10 | Month | 27 | Day |
Unpublished
Completed
2014 | Year | 07 | Month | 16 | Day |
2014 | Year | 10 | Month | 02 | Day |
2014 | Year | 10 | Month | 27 | Day |
2019 | Year | 02 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017746